Mirtazapine in Alzheimer-associated Weight Loss

Weight loss is a frequent problem associated with Alzheimers disease (AD). Mirtazapine has weight loss as a frequent side effect.

The aim of this retrospective study is to check whether mirtazapine 30 mg (once daily) can counteract weight loss in patients with AD or mixed dementia (AD + vascular).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Alzheimer's Disease Alzheimer Disease Body Weight Body Weight Changes Brain Diseases Central Nervous System Diseases Dementia Mental Disorders Mixed Dementia Mixed Dementias Nervous System Diseases Neurocognitive Disorders Neurodegenerative Diseases Pathological Conditions, Signs and Symptoms Signs and Symptoms Tauopathies Weight Loss

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU Brugmann

Brussels, 1020, Belgium

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

AD or mixed dementia
documented weight loss
mirtazapine 30 mg explicitly prescribed against weight loss

Exclusion criteria

no treatment compliance
other causes of weight loss
other interventions against weight loss

Treatment and study plan

mirtazapine

Drug

30 mg at bedtime

Other names: Remergon

Primary outcomes

body weight

Time frame: 6 months

Sponsors and collaborators

Lead sponsor

Brugmann University Hospital

Other

Registry information

Official study title

Mirtazapine in Alzheimer-associated Weight Loss: a Retrospective Phase IV Study

Important dates

Study start: 2004
Primary completion: 2011
Study completion: 2011
First posted: Jan 6, 2012
Registry last updated: Jan 6, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed